Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines

Peter L. Greenberg, Richard M. Stone, Rafael Bejar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Amir T. Fathi, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Virginia Klimek, Rami Komrokji, Lisa A. Kujawski, Lori J. Maness, Margaret R. O'DonnellDaniel A. Pollyea, Bart Scott, Paul J. Shami, Brady L. Stein, Peter Westervelt, Benton Wheeler, Dorothy A. Shead, Courtney Smith

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations

Abstract

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.

Original languageEnglish (US)
Pages (from-to)261-272
Number of pages12
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number3
DOIs
StatePublished - Mar 1 2015

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this